PMS2 Recombinant Monoclonal Antibody

Code: CSB-RA927547A0HU

Rate （N/A）
Review （0）

Size:

50μl100μl

US$210

Quantity:

Species Reactivity: Human

Application: ELISA, WB, IHC

Send an Inquiry

Start an on-line Chat

Online ordering is currently available for U.S. customers only. For orders outside the U.S., please kindly submit an inquiry or start a chat with us.

Product Details
Related Products
Customer Reviews and Q&A
Target Background

Product Details

Uniprot NO.

P54278

Target Names

PMS2

Alternative Names

DNA mismatch repair gene homologue antibody; DNA mismatch repair protein PMS2 antibody; H_DJ0042M02.9 antibody; HNPCC4 antibody; Mismatch repair endonuclease PMS2 antibody; Mismatch repair gene PMSL2 antibody; MLH4 antibody; PMS 2 antibody; PMS1 homolog 2 mismatch repair system antibody; PMS1 protein homolog 2 antibody; PMS2 antibody; PMS2 postmeiotic segregation increased 2 antibody; PMS2 postmeiotic segregation increased 2 (S. cerevisiae) antibody; PMS2_HUMAN antibody; PMS2CL antibody; PMSL2 antibody; Postmeiotic segregation increased; S. cerevisiae; 2 antibody

Species Reactivity

Human

Immunogen

A synthesized peptide derived from human PMS2

Conjugate

Non-conjugated

Clonality

Monoclonal

Isotype

Rabbit IgG

Clone No.

5D3

Purification Method

Affinity-chromatography

Concentration

It differs from different batches. Please contact us to confirm it.

Buffer

Rabbit IgG in 10mM phosphate buffered saline , pH 7.4, 150mM sodium chloride, 0.05% BSA, 0.02% sodium azide and 50% glycerol.

Form

Liquid
Note: We will preferentially ship the format that we have in stock, however, if you have any special requirement for the format, please remark your requirement when placing the order, we will prepare according to your demand.

Scope Application

ELISA Protocol Western Blotting(WB) Protocol Immunohistochemistry (IHC) Protocol

Recommended Dilution

Application	Recommended Dilution
WB	1:500-1:2000
IHC	1:50-1:200

Storage

Upon receipt, store at -20°C or -80°C. Avoid repeated freeze.

Lead Time

Basically, we can dispatch the products out in 1-3 working days after receiving your orders. Delivery time maybe differs from different purchasing way or location, please kindly consult your local distributors for specific delivery time.
Note: All of our proteins are default shipped with normal blue ice packs, if you request to ship with dry ice, please communicate with us in advance and extra fees will be charged.

Usage

For Research Use Only. Not for use in diagnostic or therapeutic procedures.

Datasheet & COA

Antibody FAQs

Images

Western Blot
Positive WB detected in:HEK293 whole cell lysate(30µg), COLO-205 whole cell lysate(30µg), Hela whole cell lysate(30µg)
All lanes: PMS2 antibody at 1:1000
Secondary
Goat polyclonal to rabbit IgG at 1/40000 dilution
Predicted band size: 96 kDa
Observed band size: 120 kDa
Exposure time：3min
IHC image of CSB-RA927547A0HU diluted at 1:100 and staining in paraffin-embedded human glioma cancer performed on a Leica BondTM system. After dewaxing and hydration, antigen retrieval was mediated by high pressure in a citrate buffer (pH 6.0). Section was blocked with 10% normal goat serum 30min at RT. Then primary antibody (1% BSA) was incubated at 4°C overnight. The primary is detected by a Goat anti-rabbit polymer IgG labeled by HRP and visualized using 0.05% DAB.
Overlay Peak curve showing PC-3 cells stained with CSB-RA927547A0HU (red line) at 1:100. The cells were fixed in 4% formaldehyde and permeated by 0.2% TritonX-100 for 10min. Then 10% normal goat serum to block non-specific protein-protein interactions followed by the antibody (1ug/1*10⁶cells) for 45min at 4℃. The secondary antibody used was FITC-conjugated goat anti-rabbit IgG (H+L) at 1/200 dilution for 35min at 4℃.Control antibody (green line) was Rabbit IgG (1ug/1*10⁶cells) used under the same conditions. Acquisition of >10,000 events was performed.

Description

PMS2 serves as an essential component of the DNA mismatch repair machinery, functioning as part of the MutLα heterodimer alongside MLH1 to maintain genomic stability during replication. This protein plays a critical role in recognizing and correcting base-base mismatches and insertion-deletion loops, making it a key focus in cancer research, particularly in studies of Lynch syndrome and microsatellite instability in colorectal and other hereditary cancers.

This recombinant monoclonal antibody, clone 5D3, offers researchers the consistency and reliability that comes with sequence-defined production. Unlike traditional hybridoma-derived antibodies, recombinant technology ensures lot-to-lot reproducibility, allowing you to maintain experimental continuity across long-term studies without the variability that can compromise data interpretation.

Validation across multiple platforms demonstrates this antibody's versatility in your workflow. Western blot analysis confirms robust detection of PMS2 in HEK293, COLO-205, and HeLa whole cell lysates, with the observed band appearing at approximately 120 kDa rather than the predicted 96 kDa molecular weight. This size difference is commonly attributed to post-translational modifications, particularly glycosylation, which is characteristic of many nuclear proteins involved in DNA repair processes. Immunohistochemistry validation in paraffin-embedded human glioma tissue shows clear nuclear staining patterns consistent with PMS2's function in DNA repair, while flow cytometry analysis in PC-3 cells demonstrates suitability for single-cell applications.

This antibody supports investigations into mismatch repair deficiency, tumor progression mechanisms, and biomarker development for hereditary cancer syndromes, providing a dependable tool for both basic research and translational studies in oncology.

Customer Reviews and Q&A

■ Customer Reviews

Submit a Review here

Target Background

Function(From Uniprot)

Component of the post-replicative DNA mismatch repair system (MMR). Heterodimerizes with MLH1 to form MutL alpha. DNA repair is initiated by MutS alpha (MSH2-MSH6) or MutS beta (MSH2-MSH3) binding to a dsDNA mismatch, then MutL alpha is recruited to the heteroduplex. Assembly of the MutL-MutS-heteroduplex ternary complex in presence of RFC and PCNA is sufficient to activate endonuclease activity of PMS2. It introduces single-strand breaks near the mismatch and thus generates new entry points for the exonuclease EXO1 to degrade the strand containing the mismatch. DNA methylation would prevent cleavage and therefore assure that only the newly mutated DNA strand is going to be corrected. MutL alpha (MLH1-PMS2) interacts physically with the clamp loader subunits of DNA polymerase III, suggesting that it may play a role to recruit the DNA polymerase III to the site of the MMR. Also implicated in DNA damage signaling, a process which induces cell cycle arrest and can lead to apoptosis in case of major DNA damages.

Gene References into Functions

discover a translocation disrupting MLH1 and three mutations in MSH6 and PMS2 that increase endometrial, colorectal, brain and ovarian cancer risk PMID:28466842
The effects of chronic smoking on oral mucosa led to the methylation of genes MRE11A PMS2, XRCC1 and MLH3, but resulted in a reduction of gene expression of MRE11A and PMS2, which showed >/=50% methylation. These results provide evidence that smoking cause methylation and reduced expression of repair genes. PMID:29775861
Low PMS2 expression is associated with Colonic Adenoma and Adenocarcinoma. PMID:29976631
In a genetic analysis of 84 colorectal tumors, we found tumors from patients with PMS2-associated Lynch syndrome to be distinct from colorectal tumors associated with defects in other mismatch repair genes. PMID:29758216
our data suggests thatMSH6 Glu39Gly polymorphism is associated with the risk of developing sporadic colorectal cancer in polish population. Linkage to the female gender, onset above 60 years old and further increase of risk when combined with wild-type allele of PMS2 IVS1-1121C > PMID:28451866
MLH1 and PMS2 can be imported to the nucleus by a classical nuclear import pathway PMID:29175432
this is the first documented case of synchronous colon and prostate cancers, with isolated PMS2 loss present in the colon cancer while intact DNA mismatch repair protein expressions present in the prostate cancer PMID:30061258
Data show that MLH1(L749P) and MLH1(Y750X) make PMS2 prone to calyculin induced degradation, suggeting that the specific degradation of PMS2 may represent a new mechanism to regulate MLH1-PMS2 heterodimer protein MutLalpha. PMID:28767177
Mutation scanning results on the largest cohort published to date confirm that the highest detection rate of PMS2 mutations is found in patients with a tumor showing isolated loss of PMS2 expression in addition to germline PMS2 mutation in patients with Lynch syndrome or mismatch repair deficiency syndrome. PMID:27435373
Germline PMS2 and somatic POLE exonuclease mutations cause hypermutability of the leading DNA strand in biallelic mismatch repair deficiency syndrome brain tumours PMID:28805995
Loss of PMS2 expression is associated with colorectal carcinoma. PMID:28651545
A novel pathogenic PMS2 mutation in a mismatch repair deficiency patient PMID:27017610
High PMS2 expression is associated with the development of genetic instability and is linked to tumor aggressiveness and early PSA recurrence in prostate cancer. PMID:27803051
Data suggest that yeast Mlh1-Mlh3 heterodimer does not exhibit hallmarks of a canonical (structure-selective) Holliday junction resolvase/endonuclease; multiple Mlh1-Mlh3 heterodimers appear to load onto DNA to form an activated polymer that cleaves DNA; human MLH1-PMS2 exhibits similar characteristics. (MLH = mutL homolog protein; PMS2 = post meiotic segregation increased 2 protein) PMID:28453523
In an individual with mismatch repair deficiency syndrome, PMS2 was found to be homozygously inactivated by a complex chromosomal rearrangement. PMID:27329736
show that DNA repair genes (fan1 and pms2) significantly modify age at onset in Huntington's Disease and Spinocerebellar Ataxias, suggesting a common pathogenic mechanism, which could operate through the observed somatic expansion of repeats PMID:27044000
The results of this case study indicated that although FOXL2 402C > G mutation determines the development of granulosa cell tumor, PMS2 mutation may be the initial driver of carcinogenesis. Immunohistochemistry-based tumor testing for mismatch repair gene expression may be necessary for granulosa cell tumors to determine their malignant potential or if they are part of Lynch syndrome. PMID:28347324
A total of 201 unique disease-predisposing mismatch repair gene mutations were identified in 369 Lynch syndrome families. These mutations affected MLH1 in 40%, MSH2 in 36%, MSH6 in 18% and PMS2 in 6% of the families. PMID:27601186
molecular mechanisms linking MMR with chemoresistance and suggest that stabilization of PMS2 expression may be useful in overcoming the cisplatin resistance in EOC. PMID:26423401
PMS2 mutation carriers with retention of RNA expression developed CRC 9 years later than those with loss of RNA expression. If confirmed, this finding would justify a delay in surveillance for these cases. Cancer risk was not influenced by a parent-of-origin effect PMID:26110232
Individuals who carry a MMR gene (MLH1, MSH2, PMS2 or MSH6) mutation are at an increased risk of developing cancers at multiple sites, most notably colorectal and endometrial carcinomas. PMID:26895986
Germline mutations in MLH1, MSH2, MSH6 and PMS2 have been shown to cause Lynch syndrome. A total of 234 monoallelic PMS2 mutation carriers from 170 families were included. PMID:25856668
Loss of MLH-1/PMS-2 expression was associated with right-colon location, poor and mucinous differentiation and dense lymphocytic infiltration in colorectal adenocarcinoma. PMID:26097592
Heterozygous germline mutations in any of the mismatch repair (MMR) genes, MLH1, MSH2, MSH6, and PMS2, cause Lynch syndrome (LS), an autosomal dominant cancer predisposition syndrome. PMID:26544533
A reliable tool for accurate molecular analysis of genes containing multiple copies of highly homologous sequences and improved PMS2 molecular analysis for patients with Lynch syndrome. PMID:26320870
These results demonstrate a functional role for PMS2 to protect against prostate cancer progression by enhancing apoptosis of prostate cancer cells and by inhibiting cell proliferation, migration, and invasion in vitro as well as tumor growth in vivo. PMID:26036629
MutSalpha, proliferating cell nuclear antigen, and replication factor C activate MutLalpha endonuclease to remove the 1-nucleotide Okazaki fragment flaps PMID:26224637
Our genotype-phenotype study of c.2002A>G illustrates that an extremely low level of PMS2 expression likely delays cancer onset, a feature that could be exploited in cancer preventive intervention. PMID:25691505
Report high frequency of MLH1 germline mutations in Lynch syndrome patients with colorectal and endometrial carcinoma demonstrating isolated loss of PMS2 immunohistochemical expression. PMID:25871621
we collected information on 66 MLH1, 24 MSH2 and 6 PMS2 nucleotide variants reported to be associated with altered expression of at least one of these alternative transcripts, and in many instances reported as splicing mutations PMID:24989436
Another MMR protein PMS2 also displayed a declined expression while being in a later stage of transformation. PMID:25215298
Some uterine carcinosarcomas show loss of PMS2. PMID:25083964
Data indicate that in 98 mismatch repair gene PMS2 families ascertained from family cancer clinics that included a total of 2,548 family members and 377 proven mutation carriers. PMID:25512458
Large deletions in the PMS2 gene are the most frequent mutations found in Spanish Lynch syndrome families. PMID:23837913
MLH1 or PMS2 knockdown confered TMZ resistance. In recurrent GBM tumours, the expression of MLH1 and PMS2 was reduced when compared to primary tumours. PMID:24259277
Immunohistochemistry revealed loss of expression for MLH1, MSH2, MSH6, and PMS2 in 15, 21, 13, and 15 % of cases, respectively...we found a perfect association between MMR immunohistochemical analyses and MSI molecular investigation PMID:24643686
This report specifically focus on the protein expression profile and germline mutations of MSH6 and PMS2 genes in 50 Malaysian Lynch syndrome suspected patients. PMID:24072394
Promoter methylation of MLH1, PMS2, MSH2 and p16 is a phenomenon of advanced-stage HCCs. PMID:24400091
3' deletions in the PMS2 gene is not associated with colon cancer. PMID:23288611
PMS2 expression in endometrial carcionma was associated with BMI, however a link between BMI and maintenance of the DNA mismatch repair system is not supported. PMID:24444820
Data show that endometrial cancer screened by testing for tumor MLH1 methylation in individuals with MLH1 immunohistochemistry loss, and germline mutations exhibiting loss of MSH6, MSH2, or PMS2 or loss of MLH1/PMS2 with absence of MLH1 methylation. PMID:24323032
Pathogenic PMS2 mutations were detected in 69% of patients harbouring LS associated tumours with loss of PMS2 expression PMID:23709753
The role of co-existing germline P53 and PMS2 mutations in familial cancer syndrome development. PMID:23981578
Data show no evidence for deleterious mutations in PMS2, and suggest that findings are sufficient to exclude PMS2 as a gene for mutation testing in individuals with suspected LS based on tumoral loss of both MLH1 and PMS2 expression. PMID:23017166
hPMS2 directly binds to activated akt and induce hPMS2 degradation. PMID:23499907
Data indicate that c.137G>T and exon 10 deletion to be founder mutations in the PMS2 gene. PMID:22577899
We identified seven samples in this Lynch syndrome cohort with deletions in the 3' region of PMS2, including three previously reported samples with deletions of Exons 13-15 (two samples) and Exons 14-15. PMID:23012243
Data indicate no evidence that the SNPs associated with colorectal cancer (CRC) in the general population are modifiers of the risk for MLH1, MSH2, MSH6 and PMS2 MMR gene mutation carriers overall. PMID:23434150
Deleterious PMS2 allele generated by recombination with crossover between PMS2 and PMS2CL is associated with colorectal tumors. PMID:22585707
Insertion of an SVA element, a nonautonomous retrotransposon, in PMS2 intron 7 as a novel cause of Lynch syndrome. PMID:22461402